Non-varicose upper gastrointestinal bleeding
Conditions
Interventions
Experimental Group:The treatment was carried out using the endoscopic desealing gel device produced by Shanghai Yisimiao Medical Devices Co., LTD
Control group:Treatment is carried out using thermocoagulation and/or mechanical hemostasis
Sponsors
The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.18 age < =age < =75 age, gender unlimited 2. Confirmed as non-varicose upper gastrointestinal bleeding under gastrointestinal microscopy and requiring gastrointestinal exposure Take a tourniquet. 3. Fully understand the content of the trial, voluntarily participate in the clinical trial and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. There is a consciousness disorder or bloodless shock; 2. Bowel obstruction, gastrointestinal fistula or suspected gastrointestinal perforation; 3. Anatomy abnormal or unable to withstand an endoscopy; 4.Coagulation dysfunction (platelets 2); 5. Liver and kidney dysfunction (AST or ALT exceeding three times the upper limit of normal); SCr exceeds 3 times the normal upper limit); 6. Anticoagulant or antiplatelet drugs were used in the seven days prior to surgery; 7. Have taken glucocorticoids within 6 weeks prior to surgery (excluding inhalers, eye drops, topical ophthalmic medications); 8. Within 30 days prior to surgery, the bleeding site has undergone other endoscopic or surgical treatments; 9. Known for galactose intolerance, Lapp lactase deficiency, or uveose-galactose malabsorption; 10. Known allergy to Brilliant Blue FCF (Brilliant Blue FCF); 11. Women who are pregnant or breastfeeding; 12. Participating in clinical trials for other drugs or medical devices; 13. Circumstances that other investigators believe are not suitable to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effective rate of hemostasis within 5 minutes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of equipment usage;Incidence of re-bleeding 3 days and 30 days post-surgery.; | — |
Countries
China
Contacts
Public ContactLiao Zhuan
The First Affiliated Hospital of the Naval Medical University (Changhai Hospital, Shanghai).
Outcome results
None listed